{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-061344","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.874219+00:00","generated_at":"2026-06-27T03:06:01.666090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Zai Lab reports FY2021 results; financial details not provided in 8-K exhibit","bullets":["Announced financial results for FY2021; specific revenue and EPS figures not provided in the filing.","Forecasts peak-year sales from lung and GI cancer franchises could reach $2.5–3B by 2030.","Proposed share subdivision of ordinary shares (1:10) to increase liquidity on HKEX; shareholder vote sought.","Plans to submit NDA for efgartigimod in gMG in China in mid-2022; multiple clinical milestones.","Entered license agreements for KarXT (neuroscience) and BLU-945/701 (EGFR NSCLC) in Greater China."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-061344","json":"https://secwatch.observer/filing/0001193125-22-061344.json","markdown":"https://secwatch.observer/filing/0001193125-22-061344.md","text":"https://secwatch.observer/filing/0001193125-22-061344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000119312522061344/0001193125-22-061344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000119312522061344/d258445d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:06:01.666090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}